GTC Biotherapeutics, Laboratoire francais deal

Hematology company LFB proposed to acquire partner GTC for $0.28 per share, or about $17 million. The price is a 13% discount to GTC's close of $0.32 on Oct. 18, before the deal was announced. GTC markets ATryn, a recombinant antithrombin, in the U.S. to prevent peri-operative and peri-partum thromboembolic events in patients with hereditary antithrombin deficiency. GTC also has a preclinical Factor VIIa program for hemophilia, which is partnered with LFB. GTC said its board has formed a committee of independent directors to evaluate any transaction. LFB markets Hemoleven, a plasma Factor XI concentrate, to treat hemophilia. ...